COMPANY

Oleolive, Inc.

HQ: Shreveport, LA source · oleo.live ↗ · Southeast

Location: Shreveport, LA · source · Oct 15, 2026

Profile checked Oct 10, 2026

10NIH grants

Funding and NIH signals

NIH award NIH awarded $7K (STTR Phase I 3R41HL180136-01S1, supplement, notice Jul 22, 2026). NIH RePORTER 3R41HL180136-01S1 (Jul 22, 2026)
Evidence (1 event)
- Jul 22, 2026 · NIH RePORTER 3R41HL180136-01S1
  Organization: OLEOLIVE, INC.; City/State: SHREVEPORT, LA; Project number: 3R41HL180136-01S1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-07-22; FY total cost (award amount): 6500; Administering IC: National Heart Lung and Blood Institute; Project title: Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jul 22, 2026 Grant Government grant — STTR: $6,500 (annual award, as published), announced Jul 22, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Sep 17, 2025 Grant Government grant — STTR: $309,418 (annual award, as published), announced Sep 17, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

Funding

Last 2 years.

Jul 22, 2026 Government grant — STTR: $6,500 (annual award, as published), announced Jul 22, 2026. Agency: NIH/NHLBI. Source: government award database. source ↗
Sep 17, 2025 Government grant — STTR: $309,418 (annual award, as published), announced Sep 17, 2025. Agency: NIH/NHLBI. Source: government award database. source ↗

NIH awards 10

Annual award amounts. Total $4.4M.

Sep 20, 2023 NIH award 3R42AG065069-04S1 FY2023: $249,774 awarded for that fiscal year; activity R42 (STTR); PI CARDELLI, JAMES; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Evaluation of a dual PPAR agonist for treatmen source ↗
May 4, 2023 NIH award 5R42AG065069-04 FY2023: $805,761 awarded for that fiscal year; activity R42 (STTR); PI CARDELLI, JAMES; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Evaluation of a dual PPAR agonist for treatment source ↗
Sep 9, 2022 NIH award 2R42AG065069-03A1 FY2022: $1,692,440 awarded for that fiscal year; activity R42 (STTR); PI CARDELLI, JAMES; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Evaluation of a dual PPAR agonist for treatm source ↗
Aug 9, 2022 NIH award 1R41CA268286-01A1 FY2022: $399,998 awarded for that fiscal year; activity R41 (STTR); PI TRAN, NHAN L; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Chemosensitization of Glioblastoma by Propentofyl source ↗
May 14, 2021 NIH award 3R41CA247025-01A1S1 FY2021: $54,756 awarded for that fiscal year; activity R41 (STTR); PI EL SAYED, KHALID A; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Oleocanthal functional food products for b source ↗
Jun 1, 2020 NIH award 1R41CA247025-01A1 FY2020: $399,999 awarded for that fiscal year; activity R41 (STTR); PI EL SAYED, KHALID A; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Oleocanthal functional food products for br source ↗
May 20, 2020 NIH award 5R43AG065069-02 FY2020: $103,008 awarded for that fiscal year; activity R43 (SBIR); PI CARDELLI, JAMES; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Evaluation of a selective PPAR-gamma agonist for source ↗
Aug 19, 2019 NIH award 1R43AG065069-01 FY2019: $346,991 awarded for that fiscal year; activity R43 (SBIR); PI CARDELLI, JAMES; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Evaluation of a selective PPAR-gamma agonist for source ↗
May 27, 2019 NIH award 5R43AG061952-02 FY2019: $67,013 awarded for that fiscal year; activity R43 (SBIR); PI CARDELLI, JAMES; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Evaluation of oral oleocanthal to prevent and/or source ↗
Sep 18, 2018 NIH award 1R43AG061952-01 FY2018: $269,634 awarded for that fiscal year; activity R43 (SBIR); PI CARDELLI, JAMES; recipient as written: OLEOLIVE, INC., SHREVEPORT, LA. Evaluation of oral oleocanthal to prevent and/or source ↗